Phase 1 trial of a computationally designed pan-sarbecovirus vaccine
A vaccine whose antigen was designed entirely in silico from sarbecovirus sequence data was safe in 39 healthy volunteers and raised immune responses against SARS-CoV-2, SARS, and bat viruses that have never infected humans.
- Model
- Unknown
- Field
- Medicine
- Date
- 2026-05-18
- Human collaborators
- Alasdair P. S. Munro, Jonathan L. Heeney, Saul N. Faust
Sources
Original work
Announcement
Media coverage
What was found
Rather than target one strain, the team analysed sarbecovirus genetic data to compute a single synthetic antigen capturing structural features shared across the subgenus, on the theory that a vaccine aimed at what the family has in common survives the evolution of any one member. The candidate, pEVAC-PS, is a DNA vaccine delivered needle-free by micro fluid jet. The phase 1 dose-escalation trial ran in 39 healthy volunteers aged 18 to 50, sponsored by University Hospital Southampton NHS Foundation Trust, and reported no significant side effects.
Novelty check
Computationally designed and consensus or mosaic antigens have a long history in HIV and influenza vaccine work, and broad sarbecovirus vaccine candidates were pursued by several groups after 2020. What is new here is a first-in-human safety and immunogenicity readout for an antigen with no natural sequence, generated computationally rather than selected from circulating strains. Searched PubMed for prior phase 1 results on pan-sarbecovirus immunogens; earlier candidates in this class were preclinical at the time of publication.
Caveats and known objections
Phase 1: safety, tolerability and immunogenicity only. No efficacy claim, and immune response is not protection. n=39, healthy adults 18 to 50, so nothing follows about older or immunocompromised populations. Approval is years away and a phase 2 is planned. The autonomy grade is deliberately conservative because the public record is thin on what the computational method actually was: the reporting says artificial intelligence and machine learning without naming a model, architecture or developer, so model is recorded as Unknown rather than inferred. The bat-virus immunogenicity result is a laboratory assay against viruses that have not infected humans, not evidence of protection against a future outbreak.
Nobody outside the lab has checked this yet.
Reading the primary source closely enough to say whether it supports the claim counts as a check, and you are credited on the entry.
Or on GitHub: submit a check challenge the grade send a correction or send a pull request
Flag this for triage
Signals order the review queue and nothing else. They are never published, and they never move a grade: that takes a citation.
Entry history (1 event)
- AddedEntered the registry graded Peer reviewed and AI-assisted.
Entries are never deleted. A grade that does not hold up is downgraded on the record, with the reason beside it.
Graded peer reviewed for verification and ai-assisted for autonomy. What these mean.
Cite this entry
whataifound.org. (2026). Phase 1 trial of a computationally designed pan-sarbecovirus vaccine. whataifound.org: A Registry of AI Scientific and Mathematical Discoveries. https://whataifound.org/finding/2026-05-18-pevac-ps-sarbecovirusBibTeX
@misc{whataifound-universityofcambridge-2026-sarbecovirus,
title = {Phase 1 trial of a computationally designed pan-sarbecovirus vaccine},
author = {{whataifound.org}},
year = {2026},
howpublished = {whataifound.org: A Registry of AI Scientific and Mathematical Discoveries},
note = {Result by University of Cambridge / DIOSynVax. Verification: Peer reviewed. Autonomy: AI-assisted.},
url = {https://whataifound.org/finding/2026-05-18-pevac-ps-sarbecovirus}
}